The 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September
Shares of NewLink Genetics (NASDAQ: NLNK), a small-cap clinical-stage drug developer focused on therapies to treat cancer, skyrocketed by 25% in September, according to data from S&P Global Market Intelligence. The clear reason for the move higher is tied to an early month press release that updated trial data from an ongoing phase 2 study involving its lead drug indoximod.
The updated data, which NewLink presented at the Third International Cancer Immunotherapy Conference in Frankfurt/Mainz, Germany on Sept. 9, yielded encouraging and improved results for the company's IDO inhibitor in combination with Merck's (NYSE: MRK) cancer immunotherapy Keytruda.
Image source: Getty Images.
Source: Fool.com
Merck & Co. Inc. Stock
€117.20
-1.520%
With 49 Buy predictions and 1 Sell predictions Merck & Co. Inc. is one of the favorites of our community.
With a target price of 125 € there is a slightly positive potential of 6.66% for Merck & Co. Inc. compared to the current price of 117.2 €.
